Drug intelligence / Profile preview

AX-007

Development stage: Unknown
Lead developer: Axiom Biosciences
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intrathecal

Overview

AX-007 is a conditioned mesenchymal stem cell (cMSC) therapy developed by Axiom Biosciences for the treatment of Intraventricular Hemorrhage (IVH) in newborns. The product is based on Axiom's proprietary MSC platform technology. In 2023, AX-007 was granted Rare Pediatric Disease Designation and Orphan Disease Designation by the U.S. FDA for the treatment of IVH. While some pipeline documentation lists the program in the preclinical to Phase 1 stage, other company pipeline visualizations indicate it has reached Phase 2 development.

Beyond the preview

Go deeper on AX-007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AX-007.

Explore the full profile